1 not yet recruiting, 1 terminated. 2 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Not yet recruiting 1, Terminated 1 |
| Phase 2 | 2 | Not yet recruiting 1, Terminated 1 |
Follow Ehlers-Danlos syndrome type 3: new trials by email Literature Review of Ehlers-Danlos syndrome type 3 trials Research Report on Ehlers-Danlos syndrome type 3
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Regenerative Medicine for Joint Hypermobility and Instability Dextrose 20% Prolotherapy, Autologous Platelet-Rich Plasma, Doxycycline Hyclate Injectable (Investigational) - Ehlers-Danlos Syndrome Hypermobility Type (hEDS), Ehlers-Danlos Syndrome (EDS) | Phase 1 / Phase 2 | Not yet recruiting | Manhattan Pain Medicine, PLLC | 100 | 2027-01-15 | 2026-10-06 |
| Oxytocin for Hypermobile Ehlers-Danlos Syndrome Oxytocin, Placebo - Hypermobile Ehlers-Danlos Syndrome, Pain Assessment | Phase 1 / Phase 2 | Terminated | Baylor College of Medicine | 2 | 2022-05-13 | 2025-08-28 |
Ehlers-Danlos Syndrome (1) · Joint Dislocations (1) · Joint Instability (1) · Musculoskeletal Pain (1) · Pain (1) · Sprains and Strains (1)
Neurologic Manifestations (2) · Pathological Conditions, Signs and Symptoms (2) · Signs and Symptoms (2) · Cardiovascular Diseases (1) · Collagen Diseases (1) · Congenital Abnormalities (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Connective Tissue Diseases (1) · Genetic Diseases, Inborn (1) · Hematologic Diseases (1) · Hemic and Lymphatic Diseases (1) · Hemorrhagic Disorders (1) · Hemostatic Disorders (1) · Joint Diseases (1) · Muscular Diseases (1)
Glucose (1) · Oxytocin (1) · Prolotherapy (1)
Baylor College of Medicine (1) · Manhattan Pain Medicine, PLLC (1)
United States (1)
Brendan Lee, MD, PhD (1) · Jason Siefferman, MD (1) · Mariia Safroshkina, MD (1)